Display options
Cite
Snijders-Keilholz A, De Keizer RJ, Goslings BM, et al. Probable risk of tumour induction after retro-orbital irradiation for Graves' ophthalmopathy. Radiother Oncol. 1996;38(1):69-71doi: 10.1016/0167-8140(95)01670-8.
Snijders-Keilholz, A., De Keizer, R. J., Goslings, B. M., Van Dam, E. W., Jansen, J. T., & Broerse, J. J. (1996). Probable risk of tumour induction after retro-orbital irradiation for Graves' ophthalmopathy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 38(1), 69-71. https://doi.org/10.1016/0167-8140(95)01670-8
Snijders-Keilholz, A, et al. "Probable risk of tumour induction after retro-orbital irradiation for Graves' ophthalmopathy." Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology vol. 38,1 (1996): 69-71. doi: https://doi.org/10.1016/0167-8140(95)01670-8
Snijders-Keilholz A, De Keizer RJ, Goslings BM, Van Dam EW, Jansen JT, Broerse JJ. Probable risk of tumour induction after retro-orbital irradiation for Graves' ophthalmopathy. Radiother Oncol. 1996 Jan;38(1):69-71. doi: 10.1016/0167-8140(95)01670-8. PMID: 8850428.
Copy Download .nbib Format: NLM
Share it on
Full text links
Elsevier Science

Radiother Oncol. 1996 Jan;38(1):69-71. doi: 10.1016/0167-8140(95)01670-8.

Probable risk of tumour induction after retro-orbital irradiation for Graves' ophthalmopathy.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

A Snijders-Keilholz, R J De Keizer, B M Goslings, E W Van Dam, J T Jansen, J J Broerse

Affiliations

  1. Department of Clinical Oncology, University Hospital Leiden, Netherlands.

PMID: 8850428 DOI: 10.1016/0167-8140(95)01670-8

Abstract

Retrobulbar irradiation for Graves' ophthalmopathy is considered as a safe treatment and has recently been recommended as the initial treatment for patients with moderately severe eye problems. However, calculations using risk factors presently known reveal a theoretical risk of radiation-induced cancer of 1.2%. Therefore, the authors suggest that this treatment should be reserved for the elderly patient, for example above the age of 40-50 years.

Cited by

MeSH terms

Publication Types

LinkOut - more resources